EED-IN-5

EED-IN-5 (compound 21) (40-80 mg/kg; p.o.; twice daily; from day 9 to day 30 post immunization) dose-dependently alleviates clinical symptoms of the disease, reduces the degree of inflammatory infiltration in the spinal cord, and inhibits the activation and infiltration of dendritic cells, macrophages and pathogenic T cells in peripheral lymph nodes and the central nervous system in the experimental autoimmune encephalomyelitis (EAE) model of female C57BL/6 mice^[1].
EED-IN-5 (100 mg/kg; p.o.; twice daily; for consecutive 30 days) shows no obvious acute or subacute toxicity in the C57BL/6 mouse model (equal numbers of male and female mice). The mice exhibit normal weight gain, no significant abnormalities in routine blood test results and liver and kidney function indices, and no histopathological damage to major organs including the heart, liver, spleen, lung, and kidney^[1].
EED-IN-5 (80 mg/kg; intragastric administration (i.g.); single dose) preferentially and persistently accumulates in key immune lymph nodes including axillary, inguinal and cervical lymph nodes in healthy female C57BL/6 mice, with a concentration significantly higher than that of EED226, exhibiting favorable lymphoid tissue tropism^[1].